MeTagic

MeTagic – MCF Antibody Screening Platform

Fc engineering has become the focus of antibody drug development.

The current mutagenesis and in silico protein design methods are confined by the limited throughput and high cost, while the high-throughput phage display and yeast display technologies are not suitable for screening glycosylated Fc variants.

We would be developing an approach for screening unprecedented number of Fc variants. Fc variants with selectively enhanced FcγRIIIa or FcγRIIb binding were efficiently identified. By fine-tuning the functionality of Fc fragment, the antibodies exhibited more potent antitumor efficacy in in vitro or in vivo models comparing to the parental antibodies. The Fc engineering platform can be adopted to accelerate the development of the next generation antibody therapeutics.